# NCT02048813 (NCT02048813)

> Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02048813
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Anemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Cyclophosphamide; Fludarabine Phosphate; Ibrutinib; Laboratory Biomarker Analysis; Pharmacogenomic Study; Quality-of-Life Assessment; Rituximab
- Enrollment: 529
- Primary outcome: Progression-free Survival (PFS) Rate at 3 Years

## Commentary we found

- YouTube: 10
- Podcasts: 7
- X threads: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02048813

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02048813", "email": "<work email>"}; the inbox owner confirms by the emailed link.